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Available online at www.sciencedirect.comHuman alphaherpesviruses (aHHV) — herpes simplex virus
type 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) — infect
mucosal epithelial cells, establish a lifelong latent infection of
sensory neurons, and reactivate intermittingly to cause
recrudescent disease. Although chronic aHHV infections co-
exist with brisk T-cell responses, T-cell immune suppression is
associated with worsened recurrent infection. Induction of
aHHV-specific T-cell immunity is complex and results in poly-
specific CD4 and CD8 T-cell responses in peripheral blood.
Specific T-cells are localized to ganglia during the chronic
phase of HSV infection and to several infected areas during
recurrences, and persist long after viral clearance. These
recent advances hold promise in the design of new vaccine
candidates.
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Introduction
Herpes simplex virus type 1 (HSV-1), HSV-2 and varicella-
zoster virus (VZV) are closely related human neurotropic
alphaherpesviruses (aHHV) that are endemic worldwide.
Primary aHHV infections are acquired through the orofa-
cial (HSV-1) and genital epithelia (HSV-2), albeit HSV-1 is
a prominent cause of genital herpes in some settings, or via
aerosols (VZV) [1,2]. Upon primary infection, aHHV
establish a latent infection in sensory ganglion neurons,
allowing the virus to reactivate and cause recrudescent
disease [1,2]. Although frequently asymptomatic, HSV-1Current Opinion in Virology 2013, 3:452–460 and HSV-2 infections may cause herpes labialis (cold sores)
and genital herpes [1]. HSV reaches the ganglia via axonal
transport thereby restricting HSV infections and recur-
rences — that arise from neuronal reactivation and axonal
transport — to the same areas [1]. VZV causes varicella
(chickenpox) as a primary infection and herpes zoster (HZ;
shingles) upon reactivation [2]. Memory T-cells are pos-
tulated to traffic VZV during the viremic phase of primary
infection to the skin and ganglia leading to widespread
cutaneous varicella lesions and neuronal latency [2]. HZ
results from VZV reactivation and axonal transport to skin
causing dermatomal skin rash, frequently followed by
postherpetic neuralgia (PHN) [2]. Adaptive immunity is
pivotal for uncomplicated recovery from aHHV infection,
illustrated by severe complications observed in immuno-
compromised individuals [1,2]. A live-attenuated VZV
vaccine has been licensed for both preventive (varicella)
and immunotherapeutic (HZ) use [2]. However, there is no
vaccine for prevention or treatment of HSV-1 or HSV-2.
Recent advances in the field have shed new light on the
priming, specificity, and function of aHHV-specific T-
cells. This review will summarize and discuss current
understanding of the role of T-cell immunity in aHHV
infections, with an emphasis on the virus’ natural human
host.
HSV-1 and HSV-2
Most of our current understanding aHHV-specific T-cell
immunity is based on HSV-1 and HSV-2, largely due to
their recurrent nature and availability of small animal
models that recapitulate some aspects of human HSV
infection. While HSV-1 and HSV-2 are antigenically and
biologically distinct and have separate disease profiles in
humans, specific immune responses directed at them are
generally similar and partially overlap at both the B-cell and
T-cell level [3,4], such that data are largely interwoven and
summarized rather than separated in this review.
HSV-induced priming of naı¨ve T-cells during primary
infection has only been studied in mice. During primary
HSV infection, antigen is acquired by mobile, but unin-
fected, dendritic cells (DCs) and transported from epi-
thelial sites to draining lymph nodes [5,6]. Handoff to
lymph-node resident DCs may occur before contact with
naı¨ve CD8 T-cells [7] and different DCs may prime CD4
and CD8 T-cells [8,9]. Depending on kinetics, classic
dermal CD8a+ DC or CD8a+CD103+ DC may dominate
CD8 T-cell priming [8,10]. DC may mediate antigen
uptake by the receptor DNGR1 and by means of toll-
like receptor 3, DC may sense HSV as a danger signal towww.sciencedirect.com
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HSV-specific CD8 T-cells in PBMC of HSV-seropositive immunocompetent individuals. (a) Cells specific for amino acids 49–57 of HSV-2 gene UL49
and restricted by HLA B*0702 can represent up to 3.09% of circulating CD8 T-cells. (b) CD8 T-cells specific for amino acids 90–99 of HSV-1 gene
UL48, restricted by HLA A*0101, overexpress CLA (red histogram) compared to the remaining CD8 T-cells (gray histogram).facilitate crosspriming [11,12]. Autophagy is involved in
priming of CD4 T-cells [13]. DCs are variably permissive
for HSV infection in vitro [14], and immune evasion
molecules encoded by HSV inhibit direct antigen pres-
entation by virus-infected DC [10]. For example, the
g34.5 protein may inhibit antigen presentation via dis-
ruption of autophagy [15], and the vhs protein encoded by
UL41 counteracts NFkB translocation [16]. To date,
however, little evidence implicates direct infection of
DC as an important component of pathogenesis or immu-
nity in vivo. Adequate priming of naı¨ve HSV-specific CD8
T-cells during primary infection likely depends on cog-
nate virus-specific CD4 T-cells acting via licensure of
DCs [17]. HSV-specific CD4 T-cells may also be necess-
ary for the transition of primed CD8 T-cells into memory
T-cells [17] and may prolong DC survival during CD8 T-
cell priming [18].
The kinetics and specificity of HSV-specific T-cells during
primary infection are largely unknown in humans. After
resolution of acute infection, HSV-specific memory T-cells
are detected at moderate levels of 0.1–1% in blood of
immunocompetent individuals [19,20]. Exceptionally,
single HSV-2 peptide may be recognized by up to 3% of
blood CD8 T-cells; the relationship of such expansions to
disease severity is unknown (Figure 1a). Recently, we have
defined the specificity of peripheral blood HSV-1-specific
CD4 and CD8 T-cells towards 77 distinct proteins in
healthy individuals [19,21]. The emerging picture is
of a complex, poly-specific CD4 and CD8 T-cell response
with recognition of a median of 22 and 17 distinct HSV-1
proteins, respectively. T-cell targets include HSV proteins
present in large quantities in the virion (e.g. viral envelope,
tegument, capsid, and regulatory proteins), as well as
enzymes [19,21]. We find striking immunodominance
of HSV-1 glycoprotein or regulatory protein-reactive CD4
T-cells, with rapid tapering to a large number of
low-abundance responses recognizing many viral proteins.www.sciencedirect.com Interestingly, this HSV-specific CD4 T-cell immunodo-
minance profile is mathematically identical to that
observed for vaccinia virus (VV) [21], which causes an
acute viral infection and is completely cleared from the
host, in contrast to aHHV that cause chronic infections
[21]. Notably, HSV proteins encoded by genes UL39 (an
enzyme) and UL46 (a tegument protein) are prominent
CD4 T-cell targets, equivalent to the vaccine candidates
glycoprotein B (gB) and gD in terms of population preva-
lence [19]. For HSV-specific CD8 T-cells, typically only
a few fine specificities are detectable either using direct ex
vivo ELISPOT [19] or after enrichment by selection of
CLA-positive T-cells [22]. The immunodominant high
magnitude CD8 T-cell responses detected to date are
specific for viral tegument and capsid proteins [4,23].
HSV-2-specific CD8 T-cells in herpetic skin lesions are
predominately directed to tegument proteins and confirm
the antigenicity of immediate early (IE) proteins and
glycoproteins deduced from studies using blood [24,25].
CD8 T-cells recognizing tegument protein VP22 have
public T-cell receptor ab (TCRab) pairings [26], and
HSV-specific CD8 clonotypes, defined by TCR sequen-
cing, appear to be long-lasting and traffic from blood to
cervix and skin [27]. HSV-specific CD4 T-cells are typi-
cally multifunctional for Th1/Th0-like cytokines and, after
expansion, have brisk cytolytic potential [3,20]. Blood
HSV-specific CD8 T-cells can express high levels of
cytolytic molecules and secrete IFN-g upon antigenic
recall [4]. Counterbalancing roles for regulatory T-cells
or inhibitory receptors such as PD-1 remain largely unex-
plored in humans [28] but can have profound effects in
mice [29].
HSV-specific T-cells profoundly localize to sites of primary
and recurrent infection such as skin, cervix and eye, and to
sites of chronic latent infection in trigeminal ganglia (TG).
Recurrent HSV infections result in 10–40% of local CD8 T-
cells being HSV-specific in herpetic eye disease and skin atCurrent Opinion in Virology 2013, 3:452–460
454 Role of T cell immunity in virus infectionscrust stage [24,30,31]. Oligoclonal virus-specific CD4 and
CD8 T-cells, mostly recognizing tegument proteins (in-
cluding the UL46 and UL47 products) were detected in the
HSV-affected eye [30–33]. HSV-specific cytotoxic CD8 T-
cells accumulate near sensory nerve endings in HSV-2-
infected human skin biopsies [34,35]. Murine data support
and extend the human observations, with HSV-specific
CD8 T-cells localizing to infected skin and to latently
infected ganglia [36,37]. Tissue persistence of HSV-
specific CD8 T-cells in murine skin after viral clearance
correlated with local protection from exogenous re-inocu-
lation [36]. HSV-specific CD8 T-cells retained in murine
skin continuously patrol the epidermis and recognize rare
antigen-expressing keratinocytes [38]. In humans, CD8
T-cells show prolonged localization to the dermo-epider-
mal junction after HSV-2 healing and have an activated and
antiviral phenotype [39,40]. Like CD8 T-cells, HSV-2-
specific CD4 T-cells also display the tissue-resident mem-
ory (TRM) phenotype, persistently localizing to sites of
previously infected recurrent skin infection in humans
[40]. In the uterine cervix, HSV-2-specific CD4 T-cellsFigure 2
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Clusters of CD4 and CD8 T-cells surround HSV-1 LAT-positive neurons in hu
hybdrization (a) and CD3 by immunohistochemistry (b), showing that T-cell c
Human TG immunofluorescently stained for CD4 (red) and CD8 (green), show
cells. Dashed lines indicate neurons. Nuclei were counterstained with 40,6-dia
CD200R (e) and CD200 (f) by immunohistochemistry. Ganglion-infiltrating T
express its ligand CD200. (a, b, d–f) Sections were developed with 5-bromo
ethylcarbazole chromogen (CD3, CD69, CD200R and CD200; red color); nuc
400, and (d–f) 200.
Current Opinion in Virology 2013, 3:452–460 are abundant even when the virus is suppressed with
antivirals [23]. Both HSV-2-specific CD4 and CD8 T-cells
preferentially express CLA, and its ligand E-selectin is
upregulated in herpetic skin [23,41]. Recent data with
HSV-1-specific tetramers show that HSV-1-reactive CD8
T-cells in blood also express this homing receptor
(Figure 1b). It is unclear if this adhesion molecule is
important in inflammatory homing at times of overt
HSV recurrence or is also involved in local T-cell retention.
Taken together, these and data from other viral systems
[42] are consistent with a TRM phenotype as a specialized
subset of memory T-cells, and current efforts with vaccines
seek to optimize the generation and guidance of these cells
to the preferred anatomic site: the virus’ port d’entree [43].
HSV-1, but not VZV, infection of human TG is associated
with chronic inflammation [44,45]. Ganglion-infiltrating
T-cells are oligoclonal in nature and preferentially recog-
nize HSV-1 [45,46]. These CD8 T-cells have an activated
late-effector memory phenotype and form rosettes
around neurons including those that express HSV-1CD3 CD4 
CD8
CD200R  CD200 
(c)
(f)
Current Opinion in Virology
man TG. Consecutive TG sections were stained for HSV-1 LAT by in situ
lusters surround HSV-1 LAT+ neurons. Arrows indicate LAT+ neurons. (c)
ing that ganglionic T-cell clusters are composed of both CD4 and CD8 T-
mino-2-phenylindole. Consecutive TG sections were stained for CD3 (d),
-cells express CD200R, whereas neuron-interacting satellite glial cells
-4-chloro-3-indolyl-phosphate (LAT; black color) and 3-amino-9-
lei were counterstained with hematoxylin. Magnification: (a, b) 100, (c)
www.sciencedirect.com
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T-cells are less abundant than CD8 T-cells and appear
both in neuron-surrounding T-cell coronas as well as
along axons (Figure 2c) [45,46]. Neuron-surrounding
satellite glial cells (SGC) function as TG-resident anti-
gen presenting cells and express the T-cell inhibitory
molecules HLA-E and PD-L1 that interact with their
receptors CD94/NKG2A and PD-1 on ganglionic T-
cells to control HSV latency without neuronal damage
[47]. In addition, we recently demonstrated the poten-
tial role of the T-cell inhibitory CD200/CD200R axis in
human TG: TG-resident SGC expressed CD200 and
the interacting T-cells expressed the cognate receptor
CD200R (Figure 2d–f). The human intra-TG HSV-
specific T-cell response, involving both CD4 and
CD8 T-cells, is directed to a limited set of viral anti-
gens (Van Velzen et al., abstract 5.05, International
Herpesvirus Workshop, Calgary, August 2012). The
current data suggest that persistent local HSV-specific
T-cell responses control viral latency and reactivation
in ganglia and skin, respectively. Alternatively, rather
than recognizing latently infected neurons, ganglionic
virus-specific T-cells may be ‘mopping-up’ an HSV
reactivation that has bypassed innate immune control
by SGC. Murine studies demonstrate that deposition
[48] or attraction [49] of antigen-specific T-cells at
anatomic sites of challenge protects from exogenous
infection, but it is possible that ganglion-resident T-
cells also serve as sentinels to modulate and limit
endogenous reactivation or resultant centripetal spread,
epithelial shedding, recrudescent lesions and trans-
mission.
VZV
Compared to HSV, VZV is human-restricted pathogen.
Simian varicella virus (SVV) infection of nonhuman
primates closely resembles VZV pathogenesis in
humans and is currently being used to define T-cell
immunity in its natural host. VZV-specific T-cells are
considered essential for recovery from varicella and for
prevention of and resurgence from HZ. Varicella has an
incubation period of 10–21 days [2] and VZV-specific
T-cells become detectable one to three days after the
appearance of skin rash [50]. The site and cells
involved in priming of naı¨ve T-cells are unknown.
VZV decreases the capacity of DC to induce specific
T-cell responses by reducing surface expression of both
T-cell costimulatory molecules (i.e. CD80, CD83 and
CD86) and human leukocyte antigen type I (HLA-I)
and human leukocyte antigen type II (HLA-II) [51,52].
In addition, the virus reduces HLA-I expression
and inhibits IFN-g-induced HLA-II expression on
VZV-infected cells to escape CD8 and CD4 T-cell
recognition, respectively [53–56]. VZV hinders
T-cell recognition of VZV-infected keratinocytes
by inhibiting intercellular adhesion molecule 1
(ICAM-1) expression [57].www.sciencedirect.com The magnitude of the VZV-specific T-cell response
initiated during primary infection inversely correlates
with the severity of varicella and termination of viremia
[50,58]. Studies on SVV indicate that CD4 T-cell immu-
nity plays a more critical role than antibody and CD8 T-
cell responses to control varicella [59]. Compared to
HSV, studies on local tissue-restricted VZV-specific T-
cells are scarce. Yet, both CD4 and CD8 T-cells are
known to infiltrate the dermis of varicella and HZ patients
[57,60–62], possibly relocating via skin-homing receptors
[58]. The local VZV-specific T-cell response in patients
with VZV-induced uveitis is more comprehensively
characterized. Intra-ocular T-cells recognize a wide
variety of VZV proteins, secrete Th1/Th0-like cytokines,
have cytolytic potential, and are able to inhibit virus
replication in retinal pigmented epithelial cells [63–65].
The combined data suggest a detrimental role of VZV-
specific T-cells in the pathology of VZV uveitis.
Memory VZV-specific T-cells are maintained at a low
frequency [66], likely involving exogenous re-exposure to
VZV or endogenous (subclinical) reactivation, and have a
mixed central and effector memory phenotype
[52,58,67,68]. Circulating VZV-specific memory CD4
T-cells are commonly CLA-negative and preferentially
express CD38 and PD-1 [67,68], suggesting recent anti-
genic stimulation and/or exhaustion. Although similar
frequencies of circulating VZV-specific CD4 and CD8
cytotoxic T-cells have been reported [69,70], recent
studies indicate that VZV-specific CD8 T-cells are less
abundant than CD4 T-cells [52,71,72]. T-cell reactivity to
VZV antigens include structural proteins including the
glycoproteins gB, gC, gE, gH, gI and the IE proteins IE4,
IE62 and IE63 [67–70,72–77]. However, the latter studies
were restricted to the analysis of only a limited set of virus
proteins, which does not allow identification of the immu-
nodominant T-cell antigens involved in protection and
immunopathogenesis.
It is well established that the risk of HZ increases with age
[78]. This is largely attributed to the decline of VZV-
specific T-cell immunity, but not humoral immunity,
with progressing age [79–81]. Notably, the frequency
of IL-4 producing VZV-specific T-cells remains unaltered
[52,73,80,82,83,84,85,86]. Whether waning of VZV-
specific T-cell immunity reflects quantitative or qualita-
tive changes in circulating virus-specific T-cells is
unknown. Regardless, HZ induces rapid, profound and
sustained T-cell responses [87,88], so that individuals
typically develop zoster only once during their life.
The magnitude of the VZV-specific T-cell immunity
after HZ is inversely correlated with disease severity
and the risk of developing PHN [88]. Despite their
protective role in preventing reactivation, VZV-specific
T-cells have not been detected in latently infected
ganglia [45]. The data suggest that during VZV latency
no viral proteins are expressed or that the proteins are notCurrent Opinion in Virology 2013, 3:452–460
456 Role of T cell immunity in virus infectionsefficiently presented for T-cell recognition in situ
[45,89,90]. During VZV and SVV reactivation, however,
dense CD8 T-cell infiltrates have been detected in
ganglia. The limited expression of granzyme B by infil-
trating T-cells, combined with the overt expression of
CXCL10, suggest a chemokine rather than an antigen-
driven infiltration and accumulation of CD8 T-cells in
reactivated ganglia [91,92,93].
Vaccines
The only human herpesvirus vaccine available to date is
the live-attenuated VZV vaccine, which induces both B-
cell-mediated and T-cell-mediated immune responses in
vaccinated children and the elderly, thereby preventing
varicella and HZ, respectively [94–97]. However, the
current VZV vaccine protects only 80–87% and 51% of
the vaccinees against varicella and HZ, respectively
[96,98], indicating an unmet need for an improved
VZV vaccine with a higher efficacy. Furthermore, the
vaccine contains an attenuated virus that may cause mild
varicella and establishes a latent infection posing the
risk of reactivation and dissemination in the population.
Full VZV genome-wide screens of the VZV-specific
CD4 and CD8 T-cell repertoire, such as performed
recently by our groups for HSV-1 [19,21], are war-
ranted to decipher the immunodominance of VZV
proteins targeted by circulating and lesion-infiltrating
virus-specific T-cells. These studies will lead to rational
choice of candidate virus proteins for a safe and effica-
cious VZV vaccine.
There is no licensed preventive or therapeutic HSV
vaccine. Although variable formulations of HSV vaccines
induced protective immunity in mice [99], success in the
vaccine arena is yet to translate to humans. Earlier HSV-2
glycoprotein vaccines were not active to prevent primary
infection despite antibody and CD4 T-cell immunogeni-
city [100,101]. Three trials with truncated HSV-2 gD
adjuvanted with alum and 30-O-deacylated-monopho-
sphoryl lipid A showed contrasting results [102,103].
Initial studies suggested that the vaccine was efficacious
in women with no known prior HSV-1 or HSV-2 infection,
but a confirmatory study (whose endpoints included both
seroconversion and disease) showed only partial efficacy
against HSV-1 but not HSV-2 in this population. Pro-
vision of multiple effector T-cell populations with diverse
specificity seems attractive given recent data that the
CD8 and CD4 T-cell response to natural infection with
HSV-1 targets 17 and 22 proteins, respectively [19,21].
Replication-incompetent whole virus formats are advan-
cing to clinical trials [104], while replication-competent
candidates — which are highly active in challenge-esca-
lation animal models — remain interesting if safety con-
cerns can be overcome [105]. An inherently lower
immunogenicity observed with replication-incompetent
viruses relative to wild-type viruses can be overcome
with additional vaccine doses, at least in the case ofCurrent Opinion in Virology 2013, 3:452–460 orthopoxviruses such as VV [106]. It remains to be seen
if a similar strategy can be used for HSV. Therapeutic
vaccination remains a goal as an alternative to small-
molecule antivirals for the treatment of recurrent lesions
and the reduction of transmission of HSV. While a repli-
cation-incompetent whole virus candidate was inactive in
a phase 2b therapeutic clinical trial [107], a multipeptide
approach was recently shown to increase CD4 and CD8
T-cell responses in HSV-2 infected persons [108] and a
multivalent subunit candidate is under evaluation (Sko-
berne et al., abstract 6.05, International Herpesvirus
Workshop, Calgary, August 2012).
Conclusions
The T-cell responses to HSV and VZV have interesting
similarities, but also striking differences. The develop-
ment of a potent aHHV-specific T-cell immunity relies
on multifaceted DC priming of T-cells and CD4/CD8
T-cell cooperation at several stages and anatomic sites,
thus favoring vaccines that elicit complex T-cell
responses, and likely also B-cell responses to generate
long-lasting virus-neutralizing antibodies. We do not yet
know if the same T-cell antigens that are immunodo-
minant in naturally infected humans are best for
vaccines, but population prevalence at least indicates
the potential for T-cell responses and is a reasonable
criteria for candidate subunit approaches. Fascinating
recent work comparing HSV-1 seropositive persons with
and without histories of symptomatic orolabial herpes
raises the possibility that humoral response patterns to
specific proteins, or T-cell response patterns to defined
epitopes within HSV glycoproteins, may correlate with
clinical severity, offering a set of criteria for rational
down-selection of vaccine candidates [109,110]. While
poly-specific responses such as that elicited by the live-
attenuated VZV vaccine are attractive, safety concerns
persist and replication-incompetent viruses, or a multi-
valent subunit approach based on whole proteome-cov-
ering data sets, hold promise for both HSV, and for next-
generation VZV vaccines that are safe enough for immu-
nocompromised recipients. Apart from eliciting T-cell
responses to viral proteins, the emerging picture for
HSV is that one must also create a virus-specific TRM
population in both the ganglia and in the orofacial and
anogenital mucosa. In that regard, promising results of a
recent study showed that TRM can be ‘pulled’ to the site
of vaginal challenge by priming with replication-com-
petent virus at a remote site and subsequently admin-
istering CXCR3 agonist chemokines vaginally [49].
Considering therapeutic vaccination, a more thorough
understanding of the T-cell response to zoster vaccine in
adults with regards to specificity, T-cell levels and
homing, and new priming versus re-stimulation of mem-
ory, and for HSV, detailed searches for T-cell correlates
of severity, may give clues to extending and improving
the success of the existing attenuated VZV vaccine and
extending it to HSV.www.sciencedirect.com
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